EGFR is overexpressed in 50% of NSCLC patients and can activate Ras/Raf/MEK/ERK and PI3K/AKT/mTOR signaling pathways, with EGFR mutations very common in advanced NSCLC (10). Here, MTOR is linked to non-small cell lung carcinoma.